Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report

Oncology · ChemotherapiesExample report

Erdafitinib

Balversa

Use as directed

Your CYP2C9 result means somewhat lower CYP2C9 activity than usual, but the FDA gives no genetic dosing change for erdafitinib at this result.

The genes behind this label

The guidelines read one gene for erdafitinib. Each card shows the two copies this person inherited and what they mean.

CYP2C9*1/*2

Intermediate metabolizer

One copy works and one works less well.

1.5 activity scoreTypical: 2

Clears warfarin, phenytoin, celecoxib and some other pain relievers.

This result doesn't change the label.

What the guidelines say

What each guideline says about your result.

CYP2C9Intermediate metabolizer

FDA drug label

See the FDA table (U.S. Food and Drug Administration, opens in a new tab)

In plain words: Your CYP2C9 result means somewhat lower CYP2C9 activity than usual, but the FDA gives no genetic dosing change for erdafitinib at this result.
What it means: No FDA guidance for your genotype
What the label suggests: Initiate therapy with recommended starting dose.

About erdafitinib

Erdafitinib (Balversa) is a targeted cancer tablet for advanced bladder and urinary tract cancer (urothelial carcinoma) whose tumor carries certain FGFR3 gene changes.

Used for: Adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations whose disease has progressed on or after at least one prior systemic therapy

Others in oncology

Compare all 13 oncology

And 4 more

Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.

Back to the example report